The startup develops small molecule therapeutics that selectively disrupt hunger signaling to regulate energy homeostasis, providing an oral treatment for obesity and rare genetic metabolic diseases. This approach enables effective management of obesity-related conditions while preserving nutrient absorption, offering a safe therapeutic option for clinicians.
Funding
$85M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Obesity and certain rare genetic metabolic diseases are characterized by dysregulation of hunger signaling, leading to increased food intake and metabolic imbalances. Current treatments may not selectively target hunger pathways or can have systemic side effects that impact nutrient absorption. This creates a need for targeted therapies that can safely and effectively manage hunger to restore metabolic equilibrium.
Solution
Aardvark Therapeutics is developing small-molecule therapeutics that selectively modulate hunger signaling within the digestive tract to restore energy homeostasis. Their lead compound, ARD-101, is an orally administered investigational drug designed to activate bitter taste receptors (TAS2Rs) in the gut. This activation triggers the release of satiety hormones, which then activate gut-brain signals to suppress hunger. By acting locally in the digestive tract, ARD-101 aims to provide a targeted approach to managing hunger without systemic absorption, potentially minimizing off-target effects and preserving nutrient uptake. The company is focused on developing treatments for hyperphagia in rare diseases, as well as obesity and obesity-related conditions.
Target Audience
The primary target audience includes individuals with obesity, rare genetic metabolic diseases associated with hyperphagia, and clinicians specializing in endocrinology and metabolic disorders.
Features
- Oral small-molecule drug that targets hunger signaling pathways.
- Selective activation of bitter taste receptors (TAS2Rs) in the digestive tract.
- Localized action in the gut to stimulate satiety hormone release.
- Gut-brain signaling modulation to suppress hunger.
- Potential applications in Prader-Willi Syndrome, Hypothalamic Obesity, and general obesity.